UPLOAD Filing
CDT Equity Inc.
Date: April 28, 2025 · CIK: 0001896212 · Accession: 0000000000-25-004451
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-286684
Letter
Re: Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed April 22, 2025 File No. 333-286684 Dear Andrew Regan:
April 28, 2025
Andrew Regan Chief Executive Officer Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103
This is to advise you that we have not reviewed and will not review your registration statement.
Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff.
Please contact Joshua Gorsky at 202-551-7836 with any questions.
Sincerely,
Division of
Corporation Finance
Office of Life
Sciences
cc: Todd Mason, Esq.
Show Raw Text
<DOCUMENT> <TYPE>TEXT-EXTRACT <SEQUENCE>2 <FILENAME>filename2.txt <TEXT> April 28, 2025 Andrew Regan Chief Executive Officer Conduit Pharmaceuticals Inc. 4581 Tamiami Trail North, Suite 200 Naples, Florida 34103 Re: Conduit Pharmaceuticals Inc. Registration Statement on Form S-3 Filed April 22, 2025 File No. 333-286684 Dear Andrew Regan: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 and 461 regarding requests for acceleration. We remind you that the company and its management are responsible for the accuracy and adequacy of their disclosures, notwithstanding any review, comments, action or absence of action by the staff. Please contact Joshua Gorsky at 202-551-7836 with any questions. Sincerely, Division of Corporation Finance Office of Life Sciences cc: Todd Mason, Esq. </TEXT> </DOCUMENT>